CA2609733C - 6,7-unsaturated-7-carbamoyl-substituted morphinan derivative - Google Patents

6,7-unsaturated-7-carbamoyl-substituted morphinan derivative Download PDF

Info

Publication number
CA2609733C
CA2609733C CA2609733A CA2609733A CA2609733C CA 2609733 C CA2609733 C CA 2609733C CA 2609733 A CA2609733 A CA 2609733A CA 2609733 A CA2609733 A CA 2609733A CA 2609733 C CA2609733 C CA 2609733C
Authority
CA
Canada
Prior art keywords
optionally substituted
compound
chiral
lower alkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2609733A
Other languages
English (en)
French (fr)
Other versions
CA2609733A1 (en
Inventor
Masanao Inagaki
Shin-Ichiro Hara
Nobuhiro Haga
Yoshinori Tamura
Yoshihisa Goto
Tsuyoshi Hasegawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of CA2609733A1 publication Critical patent/CA2609733A1/en
Application granted granted Critical
Publication of CA2609733C publication Critical patent/CA2609733C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2609733A 2005-05-25 2006-05-25 6,7-unsaturated-7-carbamoyl-substituted morphinan derivative Active CA2609733C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2005151864 2005-05-25
JP2005-151864 2005-05-25
JP2006065762 2006-03-10
JP2006-065762 2006-03-10
PCT/JP2006/310231 WO2006126529A1 (ja) 2005-05-25 2006-05-23 ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
JPPCT/JP2006/310231 2006-05-23
PCT/JP2006/310454 WO2006126637A1 (ja) 2005-05-25 2006-05-25 ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体

Publications (2)

Publication Number Publication Date
CA2609733A1 CA2609733A1 (en) 2006-11-30
CA2609733C true CA2609733C (en) 2011-07-19

Family

ID=37451954

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2609733A Active CA2609733C (en) 2005-05-25 2006-05-25 6,7-unsaturated-7-carbamoyl-substituted morphinan derivative

Country Status (20)

Country Link
US (4) US8084460B2 (Direct)
EP (1) EP1889848B8 (Direct)
JP (1) JP4323547B2 (Direct)
KR (1) KR100912782B1 (Direct)
CN (1) CN101228172B (Direct)
AU (1) AU2006250390B2 (Direct)
BE (1) BE2019C533I2 (Direct)
BR (1) BRPI0610343B8 (Direct)
CA (1) CA2609733C (Direct)
DK (1) DK1889848T3 (Direct)
ES (1) ES2525215T3 (Direct)
FR (1) FR19C1042I2 (Direct)
HU (1) HUS1900034I1 (Direct)
MX (1) MX2007014588A (Direct)
NL (1) NL300996I2 (Direct)
PL (1) PL1889848T3 (Direct)
PT (1) PT1889848E (Direct)
RU (1) RU2403255C2 (Direct)
TW (1) TWI311056B (Direct)
WO (2) WO2006126529A1 (Direct)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
JP5714910B2 (ja) * 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド 薬学的組成物
JP5252391B2 (ja) * 2008-02-21 2013-07-31 学校法人北里研究所 オキサビシクロ［２．２．２］オクタンを有するモルヒナン誘導体およびその医薬用途
EP3342427A1 (en) * 2008-09-16 2018-07-04 Nektar Therapeutics Pegylated opioids with low potential for abuse
BR112012006069A8 (pt) * 2009-09-18 2017-10-10 Adolor Corp Método para tratar ou prevenir constipação induzida e disfunção intestinal induzida por opióide em um humano, e, uso de uma quantidade terapeuticamente efetiva de composto
CN102906099A (zh) * 2010-05-13 2013-01-30 株式会社绿十字 作为神经保护剂的基于(+)-3-羟基吗啡喃的多环衍生物
EP2639234B1 (en) 2010-11-12 2019-07-03 Shionogi&Co., Ltd. Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same
WO2013172297A1 (ja) 2012-05-14 2013-11-21 塩野義製薬株式会社 ６，７－不飽和－７－カルバモイルモルヒナン誘導体含有製剤
WO2018124062A1 (ja) 2016-12-26 2018-07-05 塩野義製薬株式会社 含量均一性を改善した製剤の製造方法
US10759756B2 (en) 2018-04-12 2020-09-01 Morphic Therapeutic, Inc. Antagonists of human integrin α4β7
KR102201609B1 (ko) 2019-04-19 2021-01-12 연성정밀화학(주) 날데메딘의 제조방법
UA130059C2 (uk) 2019-10-16 2025-10-29 Морфік Терапьютік, Інк. ІНГІБУВАННЯ ІНТЕГРИНУ <font face="Symbol">a<sub></font>4</sub><font face="Symbol">b<sub></font>7</sub> ЛЮДИНИ
WO2021100728A1 (ja) 2019-11-20 2021-05-27 塩野義製薬株式会社 ６，７－不飽和－７－カルバモイルモルヒナン誘導体含有固形製剤
CN111905111B (zh) * 2020-09-16 2023-03-31 地奥集团成都药业股份有限公司 一种评价复方谷氨酰胺组方对腹泻型肠易激综合征疗效的方法
IT202300009864A1 (it) * 2023-05-16 2024-11-16 Procos Spa Processo per la preparazione di naldemedina

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4272541A (en) 1978-06-02 1981-06-09 Miles Laboratories, Inc. 7,8 and 7-8 Substituted 4,5α-epoxymorphinan-6-one compounds, and methods of treating pain and drug dependence with them
US4275205A (en) 1980-05-05 1981-06-23 Miles Laboratories, Inc. 7,7-Ditosyloxymethyl-4,5α-epoxy-morphinan-6-ols
US4347361A (en) 1980-12-10 1982-08-31 Sisa, Incorporated 4,5α-Epoxy-3-hydroxy or methoxy-7-(1-hydroxy-alkyl or 1-oxoalkyl)morphinan-6-one compounds
US4370333A (en) 1981-06-29 1983-01-25 Sisa, Incorporated 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it
US4443605A (en) 1982-07-30 1984-04-17 Miles Laboratories, Inc. 7β-Arylalkyl-6α, 7 α-oxymethylene-3-methoxy or 3-hydroxy-4, 5α-epoxy-17 methyl or 17-cycloalkyl-methyl morphinans
US4440932A (en) 1982-09-09 1984-04-03 Miles Laboratories, Inc. 7β-Arylalkyl-7α-methyl-6-oxo or 6α-hydroxy-3-methoxy or 3-hydroxy-4,5α-epoxy-17-methyl or 17-cycloalkyl-methylmorphinans
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
DE69424853T2 (de) 1993-07-23 2000-10-05 Toray Industries, Inc. Morphinan-derivate und ihre medizinische verwendung
US5464841A (en) 1993-11-08 1995-11-07 Univ Minnesota Use of delta opioid receptor antagonists to treat immunoregulatory disorders
TR199801348T2 (xx) 1996-01-10 1998-10-21 Smithkline Beecham S.P.A. Heterosikl-kondanse morfinoid t�revleri(II).
AU5891600A (en) 1999-07-01 2001-01-22 Chemrx Advanced Technologies, Inc. Process for synthesizing oxadiazoles
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
NZ518562A (en) * 1999-11-29 2005-04-29 Adolor Corp Novel methods and compositions involving opioids and antagonists thereof
CA2408098A1 (en) 2000-05-05 2001-11-15 Pain Therapeutics, Inc. Opioid antagonist containing composition for enhancing the potency or reducing adverse side effects of opioid agonists
EP1284736A2 (en) 2000-05-05 2003-02-26 Pain Therapeutics, Inc. Opioid antagonist compositions and dosage forms
US20040024004A1 (en) 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
ES2572332T3 (es) * 2000-10-31 2016-05-31 Rensselaer Polytech Inst 2,6-metano-3-benzazocinas sustituidas en posición 8 y morfinanos sustituidos en posición 3 como ligandos de receptores opioides
CA2427931A1 (en) 2000-11-22 2002-05-30 Toray Industries, Inc. Indole derivatives and medical applications thereof
MXPA04001647A (es) * 2001-08-23 2004-05-31 Akzo Nobel Nv Proceso para la preparacion de un derivado de 14-hidroxinormorfinona.
DE10161963A1 (de) 2001-12-17 2003-07-03 Johannes Schuetz 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung
DE10229842A1 (de) * 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
CN1288158C (zh) 2002-07-11 2006-12-06 东丽株式会社 用于预防恶心和呕吐的治疗剂或预防剂
WO2004026819A2 (en) 2002-09-18 2004-04-01 The Curators Of The University Of Missouri OPIATE ANALOGS SELECTIVE FOR THE delta-OPIOID RECEPTOR
US20040157784A1 (en) 2003-02-10 2004-08-12 Jame Fine Chemicals, Inc. Opiod tannate compositions
WO2005105093A2 (en) 2003-08-26 2005-11-10 Duke University METHOD OF ARRESTING THE SIDE EFFECTS OF µ-OPIOID RECEPTOR AGONISTS DURING THEIR ADMINISTRATION
JP5266492B2 (ja) 2004-05-28 2013-08-21 ヒューマン バイオモレキュラル リサーチ インスティテュート 代謝安定性鎮痛薬、疼痛薬物療法及び他の物質の合成
US20060063792A1 (en) 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
US7142420B2 (en) 2004-09-20 2006-11-28 Qualcomm, Incorporated Devices and methods for controlling relative movement between layers of an electronic device
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
EP2639234B1 (en) 2010-11-12 2019-07-03 Shionogi&Co., Ltd. Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same

Also Published As

Publication number Publication date
EP1889848B1 (en) 2014-10-15
AU2006250390B2 (en) 2010-07-08
US20120135978A1 (en) 2012-05-31
MX2007014588A (es) 2008-01-24
EP1889848B8 (en) 2014-12-17
NL300996I1 (nl) 2019-07-03
CA2609733A1 (en) 2006-11-30
BRPI0610343B8 (pt) 2021-05-25
TWI311056B (en) 2009-06-21
NL300996I2 (nl) 2019-07-30
FR19C1042I2 (fr) 2020-06-19
WO2006126637A1 (ja) 2006-11-30
JPWO2006126637A1 (ja) 2008-12-25
JP4323547B2 (ja) 2009-09-02
CN101228172B (zh) 2013-04-03
PL1889848T3 (pl) 2015-04-30
PT1889848E (pt) 2014-12-09
RU2403255C2 (ru) 2010-11-10
EP1889848A1 (en) 2008-02-20
BE2019C533I2 (Direct) 2025-12-10
HUS1900034I1 (hu) 2019-07-29
US8084460B2 (en) 2011-12-27
ES2525215T3 (es) 2014-12-19
AU2006250390A1 (en) 2006-11-30
USRE46365E1 (en) 2017-04-11
US8536192B2 (en) 2013-09-17
TW200726470A (en) 2007-07-16
US20090203723A1 (en) 2009-08-13
WO2006126529A1 (ja) 2006-11-30
EP1889848A4 (en) 2011-08-10
KR100912782B1 (ko) 2009-08-18
RU2007148412A (ru) 2009-06-27
USRE46375E1 (en) 2017-04-25
DK1889848T3 (en) 2014-12-01
CN101228172A (zh) 2008-07-23
FR19C1042I1 (Direct) 2019-08-09
KR20080014791A (ko) 2008-02-14
BRPI0610343B1 (pt) 2020-03-10
BRPI0610343A2 (pt) 2010-06-15

Similar Documents

Publication Publication Date Title
CA2609733C (en) 6,7-unsaturated-7-carbamoyl-substituted morphinan derivative
DE69321525T2 (de) Morphinan-derivate und medizinische verwendung
US6187782B1 (en) Morphinane derivatives and medicinal use thereof
CA2861150C (en) Morphinan derivative
CN111655682B (zh) 一种高活性sting蛋白激动剂化合物
WO1995003308A1 (fr) Derive de morphinane et application medicale
JPWO1995003308A1 (ja) モルヒナン誘導体および医薬用途
WO2015006731A1 (en) Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
CA3081751A1 (en) Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same
KR20170016957A (ko) 폴리엔 마크로라이드 유도체
CN115380036A (zh) Sstr5拮抗剂
CN115043836A (zh) 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途
EP4159736A1 (en) Novel tricyclic aromatic heterocyclic compound and preparation method therefor, pharmaceutical composition and use thereof
WO2022218311A1 (en) Modulators of bcl-2 or bcl-2/bcl-xl and uses thereof
HK40121692A (zh) 一种tdg抑制剂化合物及其用途
NO et al. 3rd Phase, Bangalore 560078 (IN).
CZ2000459A3 (cs) Krystalický 10,10-bis(2-fluor-4- pyridinyl)methyl)-9(10H)-anthracenon a zlepšený způsob jeho přípravy

Legal Events

Date Code Title Description
EEER Examination request